Shire appoints Susan Kilsby as its New Chairman.
Shire has reported that Matthew Emmens will retire as non-executive chairman and Susan Kilsby, chairman of Shire’s Audit, Compliance & Risk Committee, will succeed him after the conclusion of Shire’s AGM on April 29, 2014. Emmens joined the company as chief executive in 2003 and became chairman of Shire in 2008. Kilsby joined the Shire Board as a non-executive director in September 2011. In May 2013, she was appointed chairman of Shire’s Audit, Compliance & Risk Committee. Dominic Blakemore will replace Kilsby’s position as chairman of Shire’s Audit, Compliance & Risk Committee. In addition, Kilsby’s will become a member of Shire’s Nomination Committee, effective February 1, 2014.
Source: Shire
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.